Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,457

New gene therapy helps stroke patients develop new neurons

Ischemic stroke is a condition in which parts of the brain lose their blood supply, causing nerve damage. Once brain tissue suffers irreparable harm, the patient will experience irreversible disability or death, depending on the extent of neuronal loss. However, glial cells surrounding the neurons are activated by the injury and multiply. Now, scientists have found out how to insert genes into glial cells to convert them into neurons, thus filling in for some of the lost functioning cells to improve motor functions.

There are about 86 billion neurons in the brain, but billions of them can be lost with one moderate-sized stroke. About 800,000 new strokes occur each year in the US alone. The need is to regenerate new brain cells to replace the ones that die, at least partially. This is the only known way to restore motor functions that have been impaired or destroyed by a stroke or other brain injury.

A Mother-Daughter Duo Develops What Could Be The World’s First Alzheimer’s Vaccine

Mei Mei Hu vowed to never work with her mother, Chang Yi, but she knew this was bigger than the both of them.

Having a loved one not recognize you, or forget a shared experience can be heartbreaking but that’s what Alzheimer’s does to you. We are, ultimately, nothing but the sum of our memories and experiences, so to lose the ability to remember is to lose one’s identity. Alzheimer’s is currently the sixth-largest cause for death in the United States with over 5.8 million Americans diagnosed with the memory loss disease. After 200 unsuccessful attempts worldwide to find a drug that treats Alzheimer’s, a mother-daughter duo is now close to finding a vaccine, according to Wired.

Morgan Levine at Ending Age-Related Diseases 2019

Today, we’re offering another talk from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

In her talk, Morgan Levine of the Yale School of Medicine discussed epigenetic biomarkers in detail, discussing the ways in which co-methylation networks provide insight into senescent cells and other facets of biological age.

The Brave New World of Sports

I’m excited to share my new article for The New York Times on the brave new world of #cyborg ability and coming #transhumanism sports:

I wonder whether the sporting industry might create some new competitions where — just like technology — performance-enhancing drugs are encouraged. Innovations like the new oxygen-infused injection, which might one day allow humans to hold their breath for 15 to 30 minutes, could allow competitive free divers to reach new depths, showing just how far the human body can go.

Critics will complain that the human body was not designed to compete using enhancements and that it violates the code given to us by the ancient Greeks and their first Olympics Games, where “arête,” or excellence and moral virtue, was cherished. As a longtime competitive athlete, I appreciate the sportsmanship angle; but I also think that in the 21st century we can develop both the drugs and the technology to see humans compete in new sporting events that are even more exciting than their predecessors.

It’s hard to imagine the public wouldn’t want to see swimmers with fingers surgically webbed together to act like paddles, or weight lifters using short-lasting adrenaline shots, or 150-mile-per-hour baseball pitches thrown from bionic limbs.

Drugs and performance-enhancing technology would not have to challenge any existing sporting competitions and their cultures. It would simply be a new category of sports with different athletes. And like the Cybathlon, these types of competition do more than just entertain — they lead the way forward for the medical and transhumanist industries seeking to improve the human being. Competitions would be pilgrimages for medical professionals and entrepreneurs looking to buy and possibly mass produce the latest unique technologies.

Doug Ethell at Ending Age-Related Diseases 2019

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Today, we’re releasing a talk from Dr. Doug Ethell, who announced his company’s efforts to combat Alzheimer’s disease, describing where and how this neurodegenerative disease starts and discussing his company’s work on developing therapies for the cribiform plate, which naturally clears amyloid-forming proteins from the brain before they aggregate.

Gene-editing shows promise as HIV cure in early tests

Scientists are reporting the first use of the gene-editing tool CRISPR to try to cure a patient’s HIV infection by providing blood cells that were altered to resist the AIDS virus.

The gene-editing tool has long been used in research labs and a Chinese scientist was scorned last year when he revealed he used it on embryos that led to the birth of twin girls. Editing embryos is considered too risky, partly because the DNA changes can pass to future generations.

Wednesday’s report in the New England Journal of Medicine, by different Chinese researchers, is the first published account of using CRISPR to treat a disease in an adult, where the DNA changes are confined to that person.

/* */